Combination of garadacimab and prolidase for cancer therapy
OwnerArup BHATTACHARYA, Lu YANG +1inventors
InventorsArup BHATTACHARYA, Lu YANG, Yuesheng ZHANG
Life of this patent
Estimating the term…
Abstract
A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.
Claims11
A method for therapy of cancer comprising administering to an individual in need thereof an antibody or antigen binding fragment thereof that specifically binds to Factor XII, and peptidase D (PEPD).
Dependencies are inferred from the claim text.